AU2013274815B2 - Compositions and methods for enhancing the efficacy of contraceptive microbicides - Google Patents

Compositions and methods for enhancing the efficacy of contraceptive microbicides Download PDF

Info

Publication number
AU2013274815B2
AU2013274815B2 AU2013274815A AU2013274815A AU2013274815B2 AU 2013274815 B2 AU2013274815 B2 AU 2013274815B2 AU 2013274815 A AU2013274815 A AU 2013274815A AU 2013274815 A AU2013274815 A AU 2013274815A AU 2013274815 B2 AU2013274815 B2 AU 2013274815B2
Authority
AU
Australia
Prior art keywords
composition
acid
matrix
compositions
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013274815A
Other languages
English (en)
Other versions
AU2013274815A1 (en
Inventor
Wendell Guthrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evofem Inc
Original Assignee
Evofem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013274815(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evofem Inc filed Critical Evofem Inc
Publication of AU2013274815A1 publication Critical patent/AU2013274815A1/en
Application granted granted Critical
Publication of AU2013274815B2 publication Critical patent/AU2013274815B2/en
Priority to AU2017206199A priority Critical patent/AU2017206199B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Dispersion Chemistry (AREA)
AU2013274815A 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides Ceased AU2013274815B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017206199A AU2017206199B2 (en) 2012-06-13 2017-07-19 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659368P 2012-06-13 2012-06-13
US61/659,368 2012-06-13
PCT/US2013/032510 WO2013187984A1 (en) 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017206199A Division AU2017206199B2 (en) 2012-06-13 2017-07-19 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Publications (2)

Publication Number Publication Date
AU2013274815A1 AU2013274815A1 (en) 2015-01-22
AU2013274815B2 true AU2013274815B2 (en) 2017-04-20

Family

ID=49758600

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013274815A Ceased AU2013274815B2 (en) 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides
AU2017206199A Ceased AU2017206199B2 (en) 2012-06-13 2017-07-19 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017206199A Ceased AU2017206199B2 (en) 2012-06-13 2017-07-19 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Country Status (17)

Country Link
US (7) US20150202216A1 (enExample)
EP (2) EP3308771A1 (enExample)
JP (2) JP6352907B2 (enExample)
KR (1) KR102062599B1 (enExample)
CN (2) CN104487054A (enExample)
AP (1) AP2014008149A0 (enExample)
AU (2) AU2013274815B2 (enExample)
BR (1) BR112014030984B1 (enExample)
EA (1) EA201590008A1 (enExample)
HK (1) HK1208809A1 (enExample)
IL (1) IL235812B (enExample)
MX (2) MX365905B (enExample)
NZ (1) NZ703203A (enExample)
SG (1) SG11201408243VA (enExample)
UA (1) UA115876C2 (enExample)
WO (1) WO2013187984A1 (enExample)
ZA (1) ZA201500111B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703203A (en) * 2012-06-13 2016-07-29 Evofem Inc Compositions and methods for enhancing the efficacy of contraceptive microbicides
JP2017501227A (ja) 2013-12-19 2017-01-12 エヴォフェム，インク． アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
AU2017338748A1 (en) * 2016-10-04 2019-05-02 Evofem Inc. Method of treatment and prevention of bacterial vaginosis
USD920853S1 (en) * 2018-09-14 2021-06-01 Porsche Lizenz—und Handelsgesellschaft mbH & Co. KG Bicycle
US11850303B2 (en) 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009223A1 (en) * 2000-03-07 2004-01-15 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) * 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
AU1661901A (en) 1999-11-24 2001-06-04 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
JP2009102407A (ja) 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Ｇリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
EP1399151A4 (en) 2001-06-11 2004-08-04 Merck & Co Inc METHOD FOR TREATING INFLAMMABLE DISEASES BY ADMINISTRATING A PPAR DELTA AGONIST
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
JP4712380B2 (ja) 2002-07-26 2011-06-29 三笠製薬株式会社 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
BRPI0411429A (pt) 2003-06-13 2006-07-25 Idh Holding Aps tratamento de sintomas associados com vaginose bacteriana
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
JPWO2008056786A1 (ja) 2006-11-10 2010-02-25 ロート製薬株式会社 皮膚又は粘膜適用組成物
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
CN101677980B (zh) 2007-03-30 2013-10-23 莱克瑞股份公司 乳酸低聚物在制备用于治疗妇科病的药物中的应用
AU2008256689A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
WO2009003189A1 (en) 2007-06-27 2008-12-31 Acresso Software, Inc. A method and system for software virtualization directly from an installation package
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
KR20110003534A (ko) * 2008-04-16 2011-01-12 시플라 리미티드 항진균제 및 항바이러스제를 포함하는 국소 조합물
CN101559036B (zh) * 2008-04-18 2012-02-08 上海医药工业研究院 一种阴道用避孕凝胶组合物及其制备方法和应用
WO2009155118A1 (en) 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
BRPI0803568B8 (pt) * 2008-08-14 2021-05-25 Biolab San Us Farm Ltda composição mucoaderente
US20120070476A1 (en) 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
EP2440560A1 (en) 2009-06-10 2012-04-18 Ultimorphix Technologies B.v. The succinate of tenofovir disoproxil
EP2704694A4 (en) 2011-05-02 2014-11-19 Aptalis Pharmatech Inc RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY
MX381271B (es) 2011-06-28 2025-03-11 Chemo Res Sl Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana
SG11201405778WA (en) 2012-03-19 2014-10-30 Wolff August Gmbh & Co Kg Arzneimittel Dr Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
NZ703203A (en) 2012-06-13 2016-07-29 Evofem Inc Compositions and methods for enhancing the efficacy of contraceptive microbicides
JP2015528490A (ja) 2012-09-14 2015-09-28 シプラ・リミテッド テノホビル、抗菌剤、及び任意にシクロピロックスを含む局所医薬組成物
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
WO2015070072A1 (en) 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
JP2017501227A (ja) 2013-12-19 2017-01-12 エヴォフェム，インク． アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
AU2015201042A1 (en) 2014-02-28 2015-09-17 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic Method
WO2018049326A1 (en) 2016-09-12 2018-03-15 Evofem Biosciences, Inc. Combination gel for sexually transmitted infections
AU2017338748A1 (en) 2016-10-04 2019-05-02 Evofem Inc. Method of treatment and prevention of bacterial vaginosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009223A1 (en) * 2000-03-07 2004-01-15 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Purcell et al, AIDS Res Hum Retroviruses 28(11):1389-1396 (Nov. 2012) *

Also Published As

Publication number Publication date
AU2017206199A1 (en) 2017-08-03
CN104487054A (zh) 2015-04-01
US20190133978A1 (en) 2019-05-09
KR102062599B1 (ko) 2020-01-06
KR20150018636A (ko) 2015-02-23
EP2861215A4 (en) 2015-04-22
JP2015519395A (ja) 2015-07-09
US11992472B2 (en) 2024-05-28
AP2014008149A0 (en) 2014-12-31
US10568855B2 (en) 2020-02-25
US20200147015A1 (en) 2020-05-14
JP6352907B2 (ja) 2018-07-04
US20240423936A1 (en) 2024-12-26
US20170128396A1 (en) 2017-05-11
MX2014015307A (es) 2015-07-06
WO2013187984A1 (en) 2013-12-19
NZ703203A (en) 2016-07-29
UA115876C2 (uk) 2018-01-10
MX365905B (es) 2019-06-18
IL235812A0 (en) 2015-01-29
JP6738573B2 (ja) 2020-08-12
AU2017206199B2 (en) 2019-03-28
US20150202216A1 (en) 2015-07-23
AU2013274815A1 (en) 2015-01-22
BR112014030984A2 (pt) 2017-06-27
BR112014030984B1 (pt) 2022-05-24
EA201590008A1 (ru) 2015-05-29
US20160008276A1 (en) 2016-01-14
SG11201408243VA (en) 2015-01-29
HK1208809A1 (en) 2016-03-18
EP3308771A1 (en) 2018-04-18
IL235812B (en) 2020-05-31
MX2019007176A (es) 2019-08-16
EP2861215A1 (en) 2015-04-22
JP2018109034A (ja) 2018-07-12
ZA201500111B (en) 2016-01-27
US9566232B2 (en) 2017-02-14
CN110693812A (zh) 2020-01-17
US11439610B2 (en) 2022-09-13
US20230241013A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
US11992472B2 (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
AU2020202835B2 (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
WO2015070072A1 (en) Methods for manufacturing contraceptive microbicides with antiviral properties
HK40021110A (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
OA17704A (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides.
HK40041070A (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
EA041271B1 (ru) Противозачаточная микробицидная композиция и способ предупреждения заболеваний, передающихся половым путем
HK1230485B (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
HK1230485A1 (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired